AxoGen, Inc. (AXGN)

[jimmybob]

AxoGen price target raised to $45 from $37 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou raised his price target for AxoGen to $45 saying the "solid" Q1 sets the stage for a "strong" 2018. Although the beat was modest, AxoGen "weathered disruption from changes to its sales force in January and quickly rebounded with a record March," Bijou tells investors in a post-earnings research note. The analyst, however, thinks expectations may have gotten too high and that the stock may be under pressure. He views any pullback as a buying opportunity and reiterates an Overweight rating on AxoGen